9
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and a disintegrin and metalloproteinases in hypertension and cardiac disease.

      Journal of Vascular Research
      ADAM Proteins, antagonists & inhibitors, genetics, metabolism, Animals, Antihypertensive Agents, therapeutic use, Cardiovascular System, drug effects, enzymology, Gene Expression Regulation, Enzymologic, Heart Diseases, drug therapy, Humans, Hypertension, Lipid Metabolism, Lipoproteins, Matrix Metalloproteinase 2, Matrix Metalloproteinase 7, Matrix Metalloproteinase Inhibitors, Matrix Metalloproteinases, Membrane Proteins, Signal Transduction, Transcription, Genetic

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hypertensive cardiac disease is a major cause of death worldwide. Causative factors of hypertension include environmental stressors, genetic predisposition, and common morbidities of lipid metabolism such as obesity and diabetes. These factors pathologically elevate the systemic production of vasoconstrictive G-protein-coupled receptor agonists. Pathological concentrations of these agonists upregulate the gene expression and proteolytic activity of matrix metalloproteinases (MMPs) and A disintegrin and metalloproteinases (ADAMs). Among the metalloproteinases that act in concert with other mediators to elevate the systemic blood pressure and to modulate the development of cardiovascular hypertrophy and fibrosis processes are MMP-2, MMP-7, ADAM-12, and ADAM-17. This review offers insights into the activity, differential expression, mutual regulation, and functions of these metalloproteinases. We further review evidence linking them to transcription factors, carrier proteins, and receptors for lipids. The emerging links between metalloproteinases and lipids are intriguing and suggest new therapeutic targets in hypertensive cardiac disease. Copyright © 2012 S. Karger AG, Basel.

          Related collections

          Most cited references146

          • Record: found
          • Abstract: not found
          • Article: not found

          AP-1: a double-edged sword in tumorigenesis.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Molecular mechanisms of human hypertension.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

              The matrix metalloproteinases (MMPs) mediate homeostasis of the extracellular environment. They have multiple signalling activities that are commonly altered during tumorigenesis and that might serve as intervention points for anticancer drugs. However, there are many criteria to consider in validating MMPs as drug targets and for the development of MMP inhibitors. The inhibition of some MMPs could have pro-tumorigenic effects (making them anti-targets), counterbalancing the benefits of target inhibition. These effects might partially account for the failure of MMP inhibitors in clinical trials. What are the major challenges in MMP target validation and MMP-inhibitor-drug development?
                Bookmark

                Author and article information

                Comments

                Comment on this article